Abstract
The intoxicating and medicinal properties of cannabis have been known since the human species domesticated the plant, at least 11,000 years before present. Its psychotropic constituent, (−)- trans-Δ9-tetrahydrocannabinol (Δ9-THC), exerts its pharmacological effects by binding to selective receptors present on the surface of most cells of the human body, including neurons. These receptors are normally engaged by a family of lipid-derived mediators, called endocannabinoids, which participate in the regulation of a diversity of physiological functions, including pain, mood, hunger, and memory. The endocannabinoid system (ECS) is comprised of two lipid-derived ligands, anandamide (arachidonoylethanolamide) and 2-arachidonoyl-sn-glycerol (2-AG), enzymes and transporters that control their formation and deactivation, and receptors (CB1 and CB2) that transduce their actions. All key components of the ECS are found in the brain and spinal cord but also in most if not all peripheral organs and tissues.
In this chapter, we outline current views on how endocannabinoid substances are produced, act on cannabinoid receptors, and are deactivated in the brain. In addition, we review progress on the development of pharmacological agents that interfere with endocannabinoid deactivation and discuss their potential utility in the treatment of disease.
Access provided by Autonomous University of Puebla. Download reference work entry PDF
Similar content being viewed by others
Keywords
- 2-Arachidonoyl-sn-glycerol (2-AG)
- Bioactive 2-AG metabolites
- Enzymatic steps
- Formation and deactivation
- 2-AG signalosome
- Anandamide
- Anxiety
- Cancer
- Cannabinoids
- CB1 receptor agonists
- CB1 receptor antagonists
- CB2 receptor agonists
- Chemical structures
- Cannabis addiction
- Endocannabinoid system
- Cannabinoid receptors
- Deactivation inhibitors
- Fatty acid amide hydrolase (FAAH)
- Monoacylglycerol lipase (MGL)
- N-acyl transferase (NAT) activity
- N-acylethanolamine acid amidase (NAAA)
- Perisynaptic annulus
- Phospholipase C (PLC)
- Phospholipase D (PLD)
- Schizophrenia
- Tetrahydrocannabinol
Brief History
The intoxicating and medicinal properties of cannabis have been known since the human species domesticated the plant, at least 11,000 years before present. The chemical constituent responsible for the majority of such properties – the terpenophenolic compound(−)- trans-Δ9-tetrahydrocannabinol (Δ9-THC) – was first identified in the early 1940s by American chemist Roger Adams, who also devised its first synthesis (Adams 1942). This work was soon confirmed by others (Wollner et al. 1942) and completed in 1964 by Raphael Mechoulam (Gaoni and Mechoulam 1964), who defined its precise structure (Fig. 1a). Despite these advances, the mechanism of action of Δ9-THC was strongly debated until 1988, when William Devane and Allyn Howlett discovered that synthetic molecules designed to mimic its effects, such as the compound CP-55,940 (Fig. 1b), bind to unique receptive sites and engage G proteins to inhibit adenylyl cyclase activity in brain tissue (Devane et al. 1988). The subsequent mapping of these binding sites in the rat central nervous system (CNS) (Herkenham et al. 1990) and the molecular cloning of the first cannabinoid receptor gene (Matsuda et al. 1990), now called CB1, provided definitive evidence that the mammalian brain contains a selective cell-surface receptor that recognizes Δ9-THC and underpins many of its biological actions. Shortly after the cloning of CB1, a second G protein-coupled receptor, CB2, was identified in lymphocytes and other immune cells (Munro et al. 1993).
In the years that followed, the obligatory role of cannabinoid receptors in mediating the effects of Δ9-THC and other cannabimimetic (“cannabis-like”) substances was unambiguously demonstrated using selective pharmacological tools (receptor agonists and antagonists) as well as genetic mouse models (mutant mice lacking the CB1 and CB2 receptor genes, cnr1 and cnr2) (for reviews, see Kano et al. 2009; Chevaleyre et al. 2006; Freund et al. 2003). Meanwhile, the discovery of cannabinoid (CB) receptors had launched a search for endogenous substances that might interact with these proteins. This quest culminated in the isolation of two lipid-derived molecules – anandamide (arachidonoylethanolamide) in 1992 (Devane et al. 1992) and 2-arachidonoyl-sn-glycerol (2-AG) in 1995 (Sugiura et al. 1995; Mechoulam et al. 1995) – by the laboratories of Mechoulam and Takayuki Sugiura. Many neuroscientists – accustomed to studying conventional water-soluble neurotransmitters – were initially surprised by the lipid nature of these compounds. Skepticism was eventually overcome, however, by the elucidation of the compounds’ unique biogenesis (Di Marzo et al. 1994; Stella et al. 1997), the demonstration of their “on-demand” formation and release in live brain preparations (Di Marzo et al. 1994; Stella et al. 1997; Giuffrida et al. 1999), and the progressive accumulation of evidence indicating that they function as local regulators of synaptic activity, rather than typical transmitters (for reviews, see Piomelli 2003; Piomelli et al. 2007) (more on this point later in the chapter).
The Endocannabinoid System
The endocannabinoid system is comprised of two lipid-derived messengers (the endocannabinoids anandamide and 2-AG), proteins that control their formation and deactivation, and cell-surface receptors (CB1 and CB2) that transduce their actions. The key components of endocannabinoid signaling are found in most mammalian organ systems, including the brain.
Cannabinoid Receptors
CB1 and CB2 receptors exhibit 48% amino acid sequence identity and signal through the transducing G proteins, Gi and Go (for reviews, see Mackie 2006; Freund et al. 2003). The binding of Δ9-THC and other cannabinoid agonists to these receptors causes inhibition of adenylyl cyclase activity, closing of certain voltage-gated calcium channels, opening of inwardly rectifying potassium channels, and stimulation of various protein kinases (Mackie 2006). In the brain, where CB1 is primarily localized to axon terminals, two important consequences of its activation are the suppression of neuronal excitability (via increase of K+ channel activity) and the reduction of neurotransmitter release (via inhibition of Ca2+ channel activity) (Fig. 2).
CB1 receptor expression is greatest in brain structures that are most implicated in the psychoactive effects of Cannabis. In humans and other mammals, high concentrations of CB1 are found in the neocortex, hippocampus, basal ganglia, and cerebellum. Substantial receptor levels are also present in the basolateral amygdala, hypothalamus, brain stem, and spinal cord (Mackie 2006). CB1 is also found outside the brain and spinal cord. Functionally significant amounts of the receptor are found in the small intestine, liver, white adipose tissue, pancreas, and skeletal muscle, where its presence reflects the pervasive influence exerted by the endocannabinoids on energy balance and peripheral metabolism (for reviews, see DiPatrizio and Piomelli 2012, 2015).
Activation of CB1 receptors initiates a process of desensitization that eventually renders subjects exposed to Δ9-THC and other cannabinoid agonists tolerant to the central and peripheral effects of these drugs (for a review, see González et al. 2005). This process can also occur in humans: positron emission tomography studies have shown that chronic cannabis use causes a downregulation of CB1 receptors in cortical regions of the brain and that abstinence reverses this effect (Hirvonen et al. 2012).
In addition to CB1, the brain also contains a small number of CB2 receptors, which are probably localized to neurons and microglia (Mackie 2006). However, this receptor subtype is expressed at much higher levels in cells of the peripheral immune system, including monocytes and monocyte-derived cells such as macrophages, osteoclasts, and osteoblasts (Mackie 2006). These cells also express CB1, albeit to a lesser extent than CB2, with both receptor types exerting a broad spectrum of modulatory effects on cytokine release, apoptosis, and cell migration.
2-Arachidonoyl-sn-Glycerol (2-AG)
2-AG and anandamide are the two primary endocannabinoid substances produced in mammalian tissues (Fig. 1c). Though other endogenous lipid-derived cannabinoid receptor ligands have been isolated, only 2-AG and anandamide have been consistently shown to meet three key conditions that define a neurotransmitter: activity-dependent release from neurons, modulation of synaptic transmission via activation of cell-surface receptors, and rapid deactivation (Piomelli 2003; Piomelli et al. 2007).
2-AG Formation and Degradation
At the molecular level, we understand 2-AG much better than we do anandamide. The metabolism of this fatty acyl ester, illustrated in Fig. 3, starts with the cleavage of a membrane phospholipid, phosphatidylinositol-4,5-bisphosphate (PIP2), and ends with the generation of the free fatty acid, arachidonic acid. The first steps in this pathway are sequentially catalyzed by two lipid hydrolases, phospholipase C (PLC) and diacylglycerol lipase (DGL), which are both localized to dendritic spines of excitatory synapses (Stella et al. 1997; Katona et al. 2006). PLC converts PIP2 into 1,2-diacylglycerol (1,2-DAG) (Bennett et al. 1988). This reaction is stimulated by agonist-bound Gq protein-coupled receptors (e.g., type-1 metabotropic glutamate receptors, mGluR5) and in brain tissue is mediated by the β and ε isoforms of PLC (PLC-β and PLC-ε) (Jung et al. 2005). 1,2-DAG regulates the activity of protein kinase C and other cellular effectors but also serves as substrate for two DGL isoforms (DGL-α and DGL-β), which cleave 1,2-DAG to produce 2-AG (Stella et al. 1997; Bisogno et al. 2003). Of note, 1,2-DAG can also be transformed by diacylglycerol kinase into phosphatidic acid, another intracellular second messenger (for a review, see Shulga et al. 2011).
It is common for lipid-derived messengers to be produced through multiple biogenetic routes (Piomelli et al. 2007). Another pathway that may contribute to 2-AG production involves phospholipase A1 (PLA1). This enzyme cleaves membrane phospholipids at the sn-1 position, forming arachidonic acid-containing lysophospholipids that are subsequently converted into 2-AG by a lyso-PLC activity (Pete et al. 1994) (Fig. 3).
After diffusing out of the dendritic spine, newly formed 2-AG reaches axon terminals where it encounters both CB1 receptors, which are responsible for its presynaptic actions, and the enzyme monoacylglycerol lipase (MGL), which interrupts such actions (Fig. 4). MGL is a ubiquitous serine hydrolase that converts monoacylglycerols such as 2-AG into fatty acid and glycerol (Fig. 3). It was first molecularly characterized in adipocytes, where it catalyzes the last step in triacylglycerol hydrolysis (lipolysis) (Karlsson et al. 1997), and was later shown to be also responsible for 2-AG deactivation in the brain (Dinh et al. 2002). This conclusion is supported by results obtained with pharmacological inhibitors and genetically modified mice that either lack or overexpress MGL (Hohmann et al. 2005; Jung et al. 2012a). In the brain, MGL is primarily found in axon terminals and is almost equally distributed between the cytosol and the inner aspect of the presynaptic cell membrane (Dinh et al. 2002, 2004; Gulyas et al. 2004). This localization suggests that MGL may readily gain access to the pool of 2-AG that interacts with CB1 receptors in axon terminals and, therefore, may efficiently catalyze the hydrolysis of this compound at its main site of action. Studies in a neural cell line have provided evidence that the MGL-mediated degradation of 2-AG is driven by the subsequent condensation of arachidonic acid with coenzyme A (Beltramo and Piomelli 2000), a pivotal step in phospholipid remodeling catalyzed by acyl-CoA synthetase (for a review, see Farooqui et al. 2000).
MGL accounts for about 85% of the total 2-AG hydrolase activity present in the rodent brain (Dinh et al. 2004). The remainder have been attributed to two additional serine lipases, α/β hydrolase domain-containing protein (ABHD)-6 and ABHD-12 (Blankman et al. 2007), which are also able to catalyze the hydrolysis of 2-AG in vitro. The role of ABHD-6 in terminating the actions of 2-AG remains uncertain. Data supporting such a role have been obtained for ABHD-6, the inhibition of which prolongs the effects of 2-AG at brain synapses (Jung et al. 2012a; Marrs et al. 2010). By contrast, ABHD-12 was shown to be primarily involved in the degradation of lysophosphatidylserine (Blankman et al. 2013), a phospholipid that is not directly involved in endocannabinoid signaling.
The 2-AG Signalosome
Strictly confined to an area of the dendritic spine that is adjacent to the postsynaptic density (PSD) – the so-called perisynaptic annulus – the 2-AG signalosome is a multimolecular protein complex that joins in a single functional unit, held together by scaffolding Homer proteins, three key players in 2-AG production: mGluR5, PLC-β, and DGL-α (Katona et al. 2006; Jung et al. 2007, 2012b) (Fig. 5). When glutamate released by excitatory terminals binds to mGluR5, the physical proximity of this protein to PLC-β and DGL-α enables 2-AG to be generated in large amounts within this focal area. Newly formed 2-AG leaves the postsynaptic membrane to activate CB1 receptors on adjacent nerve terminals, causing in turn a reduction in calcium channel activity and glutamate release. The fraction of 2-AG that reaches the terminals and activates CB1 may be then rapidly hydrolyzed by MGL, while the 2-AG that remains associated with the spine might be eliminated by ABHD-6, which is localized postsynaptically (Marrs et al. 2010; Jung et al. 2012b) (Fig. 5). The 2-AG signalosome was identified at excitatory synapses of the ventral striatum and prefrontal cortex (Jung et al. 2012a) but is likely to be present in other regions of the mammalian CNS (Mátyás et al. 2008; Nyilas et al. 2009). The identification of the 2-AG signalosome (Jung et al. 2012a) provides an unusual example of point-to-point lipid signaling. In contrast to classical autacoid-type signaling (e.g., by diffusible eicosanoids), this signaling modality requires that the enzymes needed to produce 2-AG be arranged in such a way as to make 2-AG-mediated retrograde transmission rapid and efficient (Fig. 6).
The structural arrangement outlined above has been documented at excitatory synapses, which contain relatively low levels of CB1 receptors (Marsicano and Lutz 1999). Inhibitory synapses formed by cholecystokinin-containing GABAergic interneurons – where retrograde signaling has been also demonstrated (for reviews, see Castillo et al. 2012 and Katona and Freund 2012) and CB1 is present in large numbers (Katona et al. 1999) – are likely to control endocannabinoid signaling through different mechanisms, which remain unknown.
Bioactive 2-AG Metabolites
The sequential action of PLC, DGL, and MGL contributes to the release of free (nonesterified) arachidonic acid from membrane phospholipids (Allen et al. 1992; Bell et al. 1979) (Fig. 3). Like other polyunsaturated fatty acids, free arachidonate is either immediately reinserted into membrane phospholipids (part of a process known as “phospholipid remodeling”) or utilized for the production of the eicosanoids, a large family of cyclooxygenase metabolites that include prostaglandins, thromboxanes, and leukotrienes (Piomelli et al. 2007). These are important bioactive lipids that control the neural response to psychological stress, body temperature, and energy homeostasis, among other processes (for reviews, see Piomelli et al. 2007; Harizi et al. 2008). 2-AG itself can be oxygenated by cyclooxygenase-2 (Cox-2) to yield a family of prostaglandin glyceryl esters, which do not bind cannabinoid receptors yet display interesting biological activities (Kozak et al. 2000). It appears that neural cells can steer 2-AG toward alternative fates of metabolic activation (e.g., formation of prostaglandin glyceryl esters) or deactivation (e.g., hydrolysis followed by arachidonic acid reesterification into phospholipids or Cox-2-dependent oxidation). The selection between these paths is likely to depend on the cells’ signaling needs, but how such selection is made and enforced is entirely unknown.
Anandamide
Figure 7 illustrates the main molecular pathways involved in the formation and degradation of anandamide. In contrast with 2-AG, the reactions leading to the production of this endocannabinoid are relatively unprecedented in lipid biochemistry, and anandamide and other members of its chemical family – the amides of ethanolamine with long-chain fatty acids (known as N-acylethanolamines or fatty acid ethanolamides) – were initially dismissed as being terminal products of post mortem tissue degradation rather than physiologically meaningful signaling molecules (Schmid et al. 1995). The functional significance – and indeed the very existence (Kempe et al. 1996) – of anandamide remained controversial until the mechanisms underlying the production and deactivation of this compound were outlined using primary cultures of rat brain neurons (Cadas et al. 1996, 1997; Di Marzo et al. 1994) and its activity-dependent release in the CNS of freely moving rats was demonstrated by using a combination of in vivo microdialysis and gas chromatography/mass spectrometry (Giuffrida et al. 1999).
Anandamide Formation
Three interconnected enzyme pathways have been implicated in anandamide production (Fig. 7). The “canonical route,” shown in the center of the figure, was elaborated in 1994–1997 (Cadas et al. 1996, 1997; Di Marzo et al. 1994). According to this model, anandamide is released by hydrolysis of the phospholipid precursor, N-arachidonoyl-phosphatidylethanolamine (N-arachidonoyl-PE), which is catalyzed by a phospholipase D (PLD) that preferentially recognizes N-acyl-substituted PE species (collectively called NAPEs) over other more common phospholipids (for a review, see Ueda et al. 2013). A unique PLD that selectively hydrolyzes NAPEs, including N-arachidonoyl-PE, was molecularly cloned (Ueda et al. 2013) and its structure was recently resolved by X-ray crystallography (Magotti et al. 2015). Nevertheless, its physiological role in anandamide formation remains to be fully elucidated (for a review, see Piomelli 2014).
The levels of the anandamide precursor, N-arachidonoyl-PE, are vanishingly low in resting neurons but quickly increase when the neurons are exposed to stimuli that elevate intracellular calcium concentrations (Cadas et al. 1996, 1997; Di Marzo et al. 1994; Stella and Piomelli 2001). For N-arachidonoyl-PE to be produced, a sequence of two distinct enzyme-mediated reactions must occur. First, arachidonic acid must be transferred from the sn-2 position of various phospholipids, where it normally resides, to the sn-1 position of lysophosphatidylcholine, producing a low-abundance phosphatidylcholine species that incorporates arachidonic acid at both sn-1 and sn-2 positions (Fig. 7). The newly generated diarachidonoyl-phosphatidylcholine gives quickly away its sn-1 acyl chain to the free amino group of phosphatidylethanolamine, generating N-arachidonoyl-PE. This reaction is catalyzed by the N-acyl transferase (NAT) activity of type-e cytosolic phospholipase A2 (Ogura et al. 2016) (Fig. 7). The sequential formation of diarachidonoyl-phosphatidylcholine and N-arachidonoyl-PE is strictly calcium-dependent and represents the rate-limiting step in the production of anandamide in intact neurons (Cadas et al. 1997).
Two detours from the canonical biosynthesis of anandamide have been proposed, both of which utilize N-arachidonoyl-PE as a starting point and substitute NAPE-PLD with one or more lipid hydrolases (Fig. 7). Macrophages exposed to the bacterial toxin, lipopolysaccharide (LPS), emit a burst of lipid mediators that include anandamide (Liu et al. 2006) and other bioactive derivatives of arachidonic acid (Dennis et al. 2010). This response is unlikely to be mediated by NAPE-PLD – the expression of which is, in fact, strongly suppressed by LPS (Zhu et al. 2011) – but rather appears to require the consecutive action of two as-yet-uncharacterized enzymes: a PLC activity that converts N-arachidonoyl-PE into phospho-anandamide and a phosphatase activity that cleaves the latter into anandamide and free phosphate (Liu et al. 2006) (Fig. 7). In addition to this PLC-initiated mechanism, N-arachidonoyl-PE may be also subjected to a double deacylation at its sn-1 and sn-2 positions, catalyzed by the enzyme ABHD-4, to produce glycerophospho-anandamide (Simon and Cravatt 2006). This intermediate may be transformed into anandamide by cleavage of its phosphodiester bond, catalyzed by the phosphodiesterase GDE1, and release of glycerol phosphate (Simon and Cravatt 2008).
The existence of multiple routes of anandamide production might reflect the diversity of physiological stimuli that are able to mobilize this endocannabinoid – which include, in neural cells, membrane depolarization, intracellular calcium transients, dopamine D 2, or oxytocin receptor activation (Di Marzo et al. 1994; Giuffrida et al. 1999; Liu et al. 2006; Lourenço et al. 2011; Steffens et al. 2003; Stella and Piomelli 2001; Wei et al. 2015). However, it is important to point out that each of the three pathways described above attributes a central place to the enzyme system that catalyzes the formation of diarachidonoyl-PC and N-arachidonoyl-PE. Since this is the only system that directs NAPE hydrolysis toward the selective production of anandamide, its full molecular characterization will be crucial to fully understand this important branch of the endocannabinoid signaling system.
Anandamide Deactivation
After release into the extracellular space, anandamide acts as a partial agonist at CB1 receptors and is subsequently deactivated by cellular uptake and intracellular hydrolysis (Fig. 8). The molecular mechanisms utilized by neural cells to degrade anandamide are reasonably well understood. Anandamide is a preferred endogenous substrate for the intracellular serine amidase, fatty acid amide hydrolase (FAAH), a member of the amidase signature family of enzymes that catalyzes the cleavage of various long-chain fatty acyl amides (Cravatt et al. 1996; Desarnaud et al. 1995; Hillard et al. 1995; Ueda et al. 1995a). Other lipid hydrolases, such as N-acylethanolamine acid amidase (NAAA) (for a review, see Ueda et al. 2010) and acid ceramidase (AC) (Li et al. 1998; for a review, see Park and Schuchman 2006), are also able to hydrolyze lipid amide bonds but show little or no affinity for anandamide and are unlikely to play an important role in its deactivation. Consistent with this view, interventions that interrupt FAAH activity cause a profound enhancement in anandamide-mediated signaling at CB1 receptors (Cravatt et al. 2001; Kathuria et al. 2003), whereas blockade of NAAA or AC exerts no such effect (Realini et al. 2013; Sasso et al. 2013).
FAAH is expressed at high levels throughout the CNS. In situ hybridization studies in the rat have shown that FAAH transcription is highest in the neocortex and hippocampus; intermediate in the cerebellum, thalamus, olfactory bulb, and striatum; and lowest in the hypothalamus, brain stem, and pituitary gland (Thomas et al. 1997). Immunohistochemical experiments largely confirmed this distribution, showing that principal neurons in the cerebral cortex, hippocampus, cerebellum, and olfactory bulb have the strongest expression of FAAH protein (Egertová et al. 1998). Many FAAH-positive neurons in the brain are found in proximity of nerve terminals that contain CB1 receptors, supporting a role for FAAH in anandamide deactivation (Egertová et al. 2003; for a review, see McKinney and Cravatt 2005). There are, however, several regions of the brain where no such correlation can be demonstrated. This discrepancy may reflect the participation of FAAH in the catabolism of “paracannabinoid” (from Greek, pará “around”) lipid amides such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), which are endogenous ligands for the nuclear receptor PPAR-α (peroxisome proliferator-activated receptor type-α) (Fu et al. 2003; for reviews, see LoVerme et al. 2005; DiPatrizio and Piomelli 2015). Supporting this idea, pharmacological inhibition of FAAH activity or genetic disruption of the faah gene results in marked increases in the levels of these FAEs, along with anandamide’s (Cravatt et al. 2001).
FAAH is housed on intracellular organelle membranes of dendritic spines (Gulyas et al. 2004). This localization raises the question of how anandamide might be able to cover the distance between its site of action (CB1 receptors on axon terminals) and its site of degradation (organelles in postsynaptic spines). There is evidence that this process is mediated through a selective carrier system present in both neurons and glial cells. This system exhibits three identifying features of a carrier-mediated transport process: first, saturation kinetics, plots of the initial rate of anandamide accumulation against extracellular anandamide concentrations yield apparent Michaelis constants that are similar to those measured for other known neurotransmitter uptake systems (Beltramo et al. 1997); second, substrate specificity, rat brain neurons and other cells in culture internalize anandamide but not closely related analogs (Beltramo et al. 1997); and third, selective inhibition, a variety of natural and synthetic compounds, including chiral analogs of anandamide, block [3H] anandamide transport in a competitive and stereospecific manner (Piomelli et al. 1999). Moreover, anandamide transport does not require FAAH, since pharmacological or genetic FAAH ablation does not interrupt its activity (Beltramo et al. 1997; Fegley et al. 2004). However, the molecular mechanism(s) underpinning anandamide transport remains disputed.
Anandamide can be also metabolized by cyclooxygenase-2, lipoxygenases, and cytochrome P450 to oxygen-containing products that display significant biological activities at as-yet-unidentified non-cannabinoid targets (Ueda et al. 1995b; Starowicz et al. 2013; for a review, see Woodward et al. 2008). An important unanswered question is whether these reactions represent an alternative path for anandamide deactivation (Kim and Alger 2004), provide a mechanism for the generation of distinct classes of lipid mediators (Starowicz et al. 2013; Woodward et al. 2008), or both.
Additional Endogenous Cannabinoid Ligands
In addition to 2-AG and anandamide, other naturally occurring lipid molecules have been shown to bind to and activate cannabinoid receptors. These include noladin ether, an ether-linked analog of 2-AG (Hanus et al. 2001); virodhamine, the ester of arachidonic acid with ethanolamine (Porter et al. 2002); and N-arachidonoyl dopamine, an endogenous vanilloid agonist that also exhibits affinity for cannabinoid receptors in vitro (Bisogno et al. 2000). However, the physiological significance of these substances, if any, remains unknown.
Cannabinoid-Based Therapeutics
European and American pharmacopeias of the late nineteenth and early twentieth century listed cannabis as an analgesic, hypnotic, and anticonvulsant (Iversen 2000; Russo 2007). The lawful use of cannabis as a medicine came to a stop in the 1930s, following the introduction in various countries, including the United States, of severe legal restrictions on its sale and use. This scenario has dramatically changed in recent years. As of March 2021, 36 states of the Union, the District of Columbia, and Guam have allowed the medical use of cannabis, quickly leading to a resurgence of its application to a variety of ailments, including glaucoma, loss of appetite, nausea, chronic pain, and muscle spasticity. Most of these indications lack adequate support from controlled clinical studies (Wei and Piomelli 2015), though many find a rational basis in the biology of the endocannabinoid system (Fig. 9). The adult nonmedical use of cannabis is legal in 15 states, the District of Columbia, the Northern Mariana Islands, and Guam. However, the drug’s ability to cause problematic use (Wei and Piomelli 2015) continues to play a major role in setting the agenda for cannabinoid-based therapeutics.
CB1 Receptor Agonists
Three currently available medications target cannabinoid receptors (for a review, see Pertwee 2012). Δ9-THC itself is marketed under the trade name of Marinol® and is used in the clinic to increase appetite in anorexic HIV patients and combat nausea caused by cancer chemotherapeutics. A synthetic analog of Δ9-THC, nabilone (Cesamet®), is prescribed in Europe for similar indications. The third approved cannabinoid-based medication is a Cannabis extract primarily composed of Δ9-THC and cannabidiol (Fig. 1a). Commercialized in Canada and several European countries under the name of nabiximols (Sativex®), this extract is utilized as a sublingual spray for the relief of pain and muscle spasticity due to multiple sclerosis and as an adjunctive analgesic treatment in cancer patients (Pertwee 2012).
In addition to Δ9-THC and nabilone, various highly potent cannabinoid agonists have been described in the literature (Fig. 1b) (for reviews, see Iversen 2001; Pertwee 2012). The therapeutic utility of these ligands is limited by their CB1-mediated psychotropic side effects, which also provide the rationale for the illicit use of some of them as an alternative to recreational marijuana (for a review, see Wells and Ott 2011). Products such as Spice, K2, and Eclipse are a blend of various herbs and spices, which have been laced with one of these synthetic cannabinoids. It is generally assumed that their effects are similar to those of Δ9-THC, but the preclinical and clinical data supporting this assumption are still limited.
CB1 Receptor Antagonists
Rimonabant (Acomplia®, previously known as SR141716A) was the first CB1 antagonist to be developed and remains one of the most extensively studied members of this class of drugs (Mackie 2006) (Fig. 10). It selectively binds to CB1 receptors with nanomolar affinity and, in most experimental settings, it behaves as an inverse agonist (Mackie 2006). (“Inverse agonists” elicit pharmacological responses that are opposite to those exerted by agonists. “Neutral antagonists” (or simply “antagonists”) block the access of agonists to their receptors without producing a response.) An important effect of rimonabant and other CB1 antagonists is to counteract the regulatory control exerted by endocannabinoid substances on central and peripheral mechanisms of energy conservation (DiPatrizio and Piomelli 2012). In obese animals and humans, this effect translates into significant improvements in lipid profiles, central obesity, and insulin resistance, along with a sustained albeit moderate weight loss (for a review, see Engeli 2012). The therapeutic potential of CB1 antagonists is limited, however, by the fact that the endocannabinoids can also strongly influence the activity of neural circuits involved in the regulation of stress responses, affect, mood, and motivation (for a review, see Clapper et al. 2009). Indeed, treatment with CB1 antagonists produces in humans a series of psychiatric adverse events (including anxiety, depression, and suicidal thoughts), which have led to stop their clinical development as anti-obesity medications (Engeli 2012). An alternative approach that is currently under investigation is the use of peripherally restricted antagonists to target CB1 receptors in the adipose organ, pancreas, and liver. In preclinical models, these receptors have been shown to play important roles in the anti-obesity effects of CB1 blockade (Tam et al. 2010).
Considering the complex changes in brain circuits and pleomorphic mechanisms underlying problematic substance use, it is not surprising that no unifying theme has been identified for the function of endocannabinoid signaling in these conditions. Nevertheless, it is notable that preclinical and human clinical studies have pointed to a pivotal role for the endocannabinoid system in nicotine addiction. For example, CB1 antagonists prevent nicotine-induced conditioned place preference and nicotine-induced dopamine release in the nucleus accumbens (Castane et al. 2002; Cohen et al. 2002). These actions suggest that CB1 receptor blockade may decrease the strength of specific environmental cues associated with nicotine intake. However, there is no clinical evidence supporting the use of CB1 receptor antagonism in smoking cessation (for a review, see Cahill et al. 2013). It is notable that the endocannabinoid system is also implicated in the reinforcing effects of alcohol, heroin, and cocaine. For example, CB1 activation enhances alcohol consumption, while CB1 blockade has the opposite effect. Genetic deletion of the CB1 receptor reduces alcohol-induced conditioned place preference (Thanos et al. 2005). Likewise, administration of CB1 antagonists or genetic deletion of CB1 receptors reduced cocaine-seeking behavior of mice (Soria et al. 2005; Orio et al. 2009; for review, see Maldonado et al. 2006).
CB2 Receptor Agonists
A particularly attractive feature of selective CB2 receptor agonists as therapeutics is that they are seemingly devoid of central side effects. Nevertheless, a number of preclinical studies have shown that these agents are highly effective in animal models of chronic neuropathic pain, peripheral inflammation, and sensitization (Ibrahim et al. 2003; Hohmann et al. 2004). They also appear to be useful in combating cocaine addiction (Xi et al. 2011), through a mechanism that remains unclear, and in counteracting bone loss, which is suggestive of a potential application in osteoporosis. Supporting this theory, a single nucleotide polymorphism (SNP) in the CB2 receptor gene strongly correlates with osteoporosis in a cohort of women (Karsak et al. 2005).
Endocannabinoid Deactivation Inhibitors
The psychiatric adverse events associated with the use of Δ9-THC and its synthetic mimics are an obstacle to broader clinical development. As a potential alternative, the endocannabinoid system offers several opportunities to circumvent such events and possibly achieve adequate therapeutic efficacy. In particular, both FAAH inhibitors and MGL inhibitors have reached clinical testing and are currently being considered for the treatment of a variety of conditions including social anxiety, cannabis use disorder (i.e., dependence and withdrawal), and chronic pain. Intriguing data also suggest a possible application in schizophrenia.
Anxiety
The hypothesis that anandamide is an important regulator of stress-coping behaviors was first suggested by animal experiments, which showed that the FAAH inhibitor URB597 decreases isolation-induced ultrasonic vocalizations in rat pups and increases the time spent by adult rats in the open arms of an elevated maze (Kathuria et al. 2003). Subsequent studies found that URB597 also enhances active stress-coping behaviors in mouse and rat models of acute and chronic stress (Gobbi et al. 2005; Bortolato et al. 2007). Other FAAH inhibitors were later shown to exert anxiolytic-like effects that were similar to those of URB597 (Bluett et al. 2014). Such effects are prevented by administration of a CB1 inverse agonist, an indication that they are due to enhanced anandamide-mediated transmission at CB1 receptors. Further implicating anandamide in response to stressful stimuli, a study in healthy volunteers showed that the circulating levels of anandamide were elevated after exposing the subjects to a psychosocial stress test (Dlugos et al. 2012). In this context, it is important to point out that URB597 has no rewarding effects in rodents (Gobbi et al. 2005) and is not self-administered by squirrel monkeys (Justinova et al. 2008), marking a clear mechanistic distinction with Δ9-THC and suggesting that FAAH inhibitors might be used in the clinic without risk of abuse. Human studies have confirmed that anandamide signaling controls the emotional response to stress, possibly through modulation of prefrontal cortical-amygdala circuits (for a review, see Patel et al. 2017). For example, individuals who carry the non-synonymous FAAH polymorphism C385A, who exhibit higher plasma levels of anandamide, show increased fronto-amygdalar connectivity and cued fear extinction (Dincheva et al. 2015). Moreover, administration of the FAAH inhibitor PF-04457845 to human volunteers was found to improve the recall of fear extinction memories and to attenuate the anxiogenic effects of stress in healthy subjects (Mayo et al. 2020). Similarly, a structurally different FAAH inhibitor, JNJ-42165279, was shown to dampen activation of several brain structures involved in anxiety – including the amygdala, anterior cingulate, and insula – during an emotion face-processing task (Paulus et al. 2021). The same drug was also was tested in a multicenter, placebo-controlled Phase-2 trial in persons with social anxiety disorder. This trial reported statistically detectable signs of efficacy, but the dosage used was deemed insufficient to block FAAH (Schmidt et al. 2021). Further testing in human anxiety and trauma/stressor-related disorders is warranted.
Cannabis Addiction
The pharmacological profile of FAAH inhibitors predicts that they should alleviate many of the symptoms experienced by abstinent marijuana addicts – including anxiety, depression, and deterioration of sleep quality (for a review, see Clapper et al. 2009). A randomized double-blind clinical trial aimed at determining the safety and efficacy of the compound PF-04457845, a FAAH inhibitor that is structurally different from URB597, showed that this agent is effective in reducing cannabis use and alleviating cannabis withdrawal symptoms in men (D’Souza et al. 2019). A replication study is ongoing at the time of this writing, and its outcome will likely influence future research directions in other areas of addiction medicine, such as tobacco (Justinova et al. 2015) and cocaine use disorder (Adamczyk et al. 2009; for reviews, see Panlilio et al. 2013; Piomelli 2014).
Pain
A large body of preclinical evidence points to the ECS as a critical regulator of pain processing (for reviews, see Soliman et al. 2021). The phenotype of individuals who carry loss-of-function FAAH mutations – including C385A and FAAH-OUT – have lent support to this conclusion (Greenbaum et al. 2012; Habib et al. 2019), but so far the results of clinical trials have been disappointing (Huggins et al. 2012; Wagenlehner et al. 2017).
Schizophrenia
Autoradiography and positron emission tomography studies have shown that CB1 receptor densities are elevated in cortical and subcortical areas of human subjects with schizophrenia (Wong et al. 2010). These results are sometimes interpreted as suggesting that excessive endocannabinoid transmission might be a causative factor in psychosis (Andreasson et al. 1987), but data from other studies offer an opposing perspective. First, a simplistic “endocannabinoid hypothesis of schizophrenia” is negated by the fact that the CB1 antagonist rimonabant did not significantly improve disease symptoms in a placebo-controlled clinical trial of subjects with schizophrenia (Meltzer et al. 2004) or in a subsequent double-blind placebo-controlled trial aimed at assessing the impact of the drug on cognitive function in schizophrenic subjects (Boggs et al. 2012). Second, a study in non-medicated first-episode persons with psychosis showed that cerebrospinal levels of anandamide correlate inversely with positive and negative symptoms of schizophrenia (Leweke et al. 2007). Third, in a double-blind randomized clinical trial of cannabidiol in acute psychosis, treatment with the drug was accompanied by a substantial increase in circulating anandamide levels, which was significantly associated with clinical improvement (Leweke et al. 2012). Finally, in patients in the prodromal states of schizophrenia, lower cerebrospinal levels of anandamide were linked with higher risk of an earlier transition to psychosis (Koethe et al. 2009). These results are consistent with animal studies suggesting that anandamide signaling in the basal ganglia of rats and mice may be part of a negative feedback loop that offsets the effects of excessive dopaminergic activity (for a review, see van der Stelt and Di Marzo 2003). Thus, a substantial number of findings support the conclusion that anandamide may act as a homeostatic controller of dopamine neurotransmission and a protective signal in schizophrenia. A corollary of this hypothesis is that FAAH inhibitors may be beneficial in psychosis and, possibly, in other mental disorders in which hyperactive dopamine transmission might be implicated (e.g., Tourette’s syndrome).
Outlook
Research on the endocannabinoid system has greatly expanded our understanding on these unique signaling molecules and the roles they play in health and disease. Information gleamed from studies on cannabis has illuminated how Δ9-THC and other exogenous cannabinoids hijack the endocannabinoid signaling system, leading to unwanted effects but at the same time providing promising opportunities for therapeutic intervention. While important questions remain, it is nevertheless clear that the therapeutic potential of endocannabinoid modulation calls for further basic and clinical investigation.
References
Adamczyk P, McCreary AC, Przegalinski E, Mierzejewski P, Bienkowski P, Filip M (2009) The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. J Physiol Pharmacol 60(3):119–125
Adams R (1942, February 19) Marihuana: Harvey lecture. Bull N Y Acad Med 18(11):705–730
Allen AC, Gammon CM, Ousley AH, McCarthy KD, Morell P (1992) Bradykinin stimulates arachidonic acid release through the sequential actions of an sn-1 diacylglycerol lipase and a monoacylglycerol lipase. J Neurochem 58(3):1130–1139
Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483–1486
Bell RL, Kennerly DA, Stanford N, Majerus PW (1979) Diglyceride lipase: a pathway for arachidonate release from human platelets. Proc Natl Acad Sci U S A 76(7):3238–3241
Beltramo M, Piomelli D (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11(6):1231–1235
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277(5329):1094–1097
Bennett CF, Balcarek JM, Varrichio A, Crooke ST (1988) Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature 334(6179):268–270
Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351(Pt 3):817–824
Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163(3):463–468
Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14(12):1347–1356
Blankman JL, Long JZ, Trauger SA, Siuzdak G, Cravatt BF (2013) ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc Natl Acad Sci U S A 110(4):1500–1505
Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S (2014) Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry 4:e408
Boggs DL, Kelly DL, McMahon RP, Gold JM, Gorelick DA, Linthicum J, Conley RR, Liu F, Waltz J, Huestis MA, Buchanan RW (2012) Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 134(2–3):207–210
Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62(10):1103–1110
Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 16(12):3934–3942
Cadas H, di Tomaso E, Piomelli D (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 17(4):1226–1242
Cahill K, Stevens S, Perera R, Lancaster T (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 5:CD009329. Review
Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43:857–867
Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76(1):70–81. Review
Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Ann Rev Neurosci 29:37–76. Review
Clapper JR, Mangieri RA, Piomelli D (2009) The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56(Suppl 1):235–243. Review
Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451–463
Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384(6604):83–87
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98(16):9371–9376
Dennis EA, Deems RA, Harkewicz R, Quehenberger O, Brown HA, Milne SB, Myers DS, Glass CK, Hardiman G, Reichart D, Merrill AH Jr, Sullards MC, Wang E, Murphy RC, Raetz CR, Garrett TA, Guan Z, Ryan AC, Russell DW, McDonald JG, Thompson BM, Shaw WA, Sud M, Zhao Y, Gupta S, Maurya MR, Fahy E, Subramaniam S (2010) A mouse macrophage lipidome. J Biol Chem 285(51):39976–39985
Desarnaud F, Cadas H, Piomelli D (1995) Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 270(11):6030–6035
Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34(5):605–613
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090):1946–1949
Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372(6507):686–691
Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC, Ra S, Gray JM, Yang R, DeGruccio AM, Huang C, Cravatt BF, Glatt CE, Hill MN, Casey BJ, Lee FS (2015) FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun 6:6395. https://doi.org/10.1038/ncomms7395. PMID: 25731744; PMCID: PMC4351757
Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99(16):10819–10824
Dinh TP, Kathuria S, Piomelli D (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66(5):1260–1264
DiPatrizio NV, Piomelli D (2012) The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci 35(7):403–411. Review
DiPatrizio NV, Piomelli D (2015) Intestinal lipid-derived signals that sense dietary fat. J Clin Invest 125(3):891–898. Review
Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H (2012) Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 37(11):2416–2427
D’Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD (2019) Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry 6(1):35–45. https://doi.org/10.1016/S2215-0366(18)30427-9. Epub 2018 Dec 6. PMID: 30528676
Egertová M, Giang DK, Cravatt BF, Elphick MR (1998) A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 265(1410):2081–2085
Egertová M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119(2):481–496
Engeli S (2012) Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 209:357–381. Review
Farooqui AA, Horrocks LA, Farooqui T (2000) Deacylation and reacylation of neural membrane glycerophospholipids. J Mol Neurosci 14(3):123–135. Review
Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A 101(23):8756–8761. https://doi.org/10.1073/pnas.0400997101. Epub 2004 May 11. PMID: 15138300; PMCID: PMC423268
Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83(3):1017–1066. Review
Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425(6953):90–93
Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647
Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2(4):358–363
Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102(51):18620–18625
González S, Cebeira M, Fernández-Ruiz J (2005) Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 81(2):300–318. Review
Greenbaum L, Tegeder I, Barhum Y, Melamed E, Roditi Y, Djaldetti R (2012) Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain 16(9):1243–1250. https://doi.org/10.1002/j.1532-2149.2012.00134.x. Epub 2012 Apr 4. PMID: 22473870
Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20(2):441–458
Habib AM, Okorokov AL, Hill MN, Bras JT, Lee MC, Li S, Gossage SJ, van Drimmelen M, Morena M, Houlden H, Ramirez JD, Bennett DLH, Srivastava D, Cox JJ (2019) Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br J Anaesth 123(2):e249–e253. https://doi.org/10.1016/j.bja.2019.02.019. Epub 2019 Mar 28. PMID: 30929760; PMCID: PMC6676009
Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98(7):3662–3665
Harizi H, Corcuff JB, Gualde N (2008) Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 14(10):461–469. Review
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87(5):1932–1936
Hillard CJ, Wilkison DM, Edgemond WS, Campbell WB (1995) Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1257(3):249–256
Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012) Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 17(6):642–649
Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004) Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308:446–453
Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435(7045):1108–1112
Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153(9):1837–1846. https://doi.org/10.1016/j.pain.2012.04.020. Epub 2012 Jun 21. PMID: 22727500
Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J et al (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100:10529–10533
Iversen LL (2000) The science of marijuana. Oxford University Press, Oxford
Iversen L (2001) Cannabinoids in pain management. Few well controlled trials of cannabis exist for systemic review. BMJ 323(7323):1250
Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68(5):1196–1202
Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D (2007) A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol 72(3):612–621
Jung KM, Clapper JR, Fu J, D’Agostino G, Guijarro A, Thongkham D, Avanesian A, Astarita G, DiPatrizio NV, Frontini A, Cinti S, Diano S, Piomelli D (2012a) 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab 15(3):299–310
Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D, Manzoni OJ (2012b) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 3:1080
Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, Goldberg SR (2008) Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 64(11):930–937
Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secci ME, Mascia P, Bandiera T, Armirotti A, Bertorelli R, Chefer SI, Barnes C, Yasar S, Piomelli D, Goldberg SR (2015) Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. Neuropsychopharmacology 40(9):2185–2197
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309–380. Review
Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272(43):27218–27223
Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, Essig J, Erxlebe E, Bab I, Kubisch C, de Vernejoul MC, Zimmer A (2005) Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14(22):3389–3396
Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9(1):76–81
Katona I, Freund TF (2012) Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35:529–558. Review
Katona I, Sperlágh B, Sík A, Käfalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19(11):4544–4558
Katona I, Urbán GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, Freund TF (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26(21):5628–5637
Kempe K, Hsu FF, Bohrer A, Turk J (1996) Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J Biol Chem 271(29):17287–17295
Kim J, Alger BE (2004) Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 7(7):697–698
Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkötter J, Piomelli D, Leweke FM (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194(4):371–372
Kozak KR, Rowlinson SW, Marnett LJ (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275(43):33744–33749
Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D (2007) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94(1–3):29–36
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94
Li CM, Hong SB, Kopal G, He X, Linke T, Hou WS, Koch J, Gatt S, Sandhoff K, Schuchman EH (1998) Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. Genomics 50(2):267–274
Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim HY, Kunos G (2006) A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A 103(36):13345–13350
Lourenço J, Matias I, Marsicano G, Mulle C (2011) Pharmacological activation of kainate receptors drives endocannabinoid mobilization. J Neurosci 31(9):3243–3248
LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D (2005) The search for the palmitoylethanolamide receptor. Life Sci 77(14):1685–1698. Review
Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101–122. Review
Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G (2015) Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. Structure 23(3):598–604
Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225–232. Review
Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G, Fung S, Lafourcade M, Alexander JP, Long JZ, Li W, Xu C, Möller T, Mackie K, Manzoni OJ, Cravatt BF, Stella N (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13(8):951–957
Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11(12):4213–4225
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561–564
Mátyás F, Urbán GM, Watanabe M, Mackie K, Zimmer A, Freund TF, Katona I (2008) Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54(1):95–107
Mayo LM, Asratian A, Lindé J, Morena M, Haataja R, Hammar V, Augier G, Hill MN, Heilig M (2020) Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized. Controlled Experimental Medicine Trial Biol Psychiatry 87(6):538–547. https://doi.org/10.1016/j.biopsych.2019.07.034. Epub 2019 Aug 13. PMID: 31590924
McKinney MK, Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. Ann Rev Biochem 74:411–432. Review
Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50(1):83–90
Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161(6):975–984
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61–65
Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I (2009) Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur J Neurosci 29(10):1964–1978
Ogura Y, Parsons WH, Kamat SS, Cravatt BF (2016) A calcium-dependent acyltransferase that produces N-acyl phosphatidylethanolamines. Nat Chem Biol 12(9):669–671. https://doi.org/10.1038/nchembio.2127. Epub 2016 Jul 11. PMID: 27399000; PMCID: PMC4990470
Orio L, Edwards S, George O, Parsons LH, Koob GF (2009) A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. J Neurosci 29:4846–4857
Panlilio LV, Justinova Z, Goldberg SR (2013) Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther 138(1):84–102. Review
Park JH, Schuchman EH (2006) Acid ceramidase and human disease. Biochim Biophys Acta 1758(12):2133–2138. Review
Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A (2017) The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev 76(Pt A):56–66. https://doi.org/10.1016/j.neubiorev.2016.12.033. PMID: 28434588; PMCID: PMC5407316
Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Chaplan SR (2021) The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial. Neuropsychopharmacology 46(5):1011–1019. https://doi.org/10.1038/s41386-020-00936-w. Epub 2020 Dec 17. PMID: 33335310
Pertwee RG (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond Ser B Biol Sci 367(1607):3353–3363. Review
Pete MJ, Ross AH, Exton JH (1994) Purification and properties of phospholipase A1 from bovine brain. J Biol Chem 269(30):19494–19500
Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4(11):873–884. Review. No abstract available
Piomelli D (2014) More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology 76 Pt B:228–234. (Review)
Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A 96(10):5802–5807
Piomelli D, Astarita G, Rapaka R (2007) A neuroscientist’s guide to lipidomics. Nat Rev Neurosci 8(10):743–754. Review
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3):1020–1024
Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D (2013) Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci Rep 3:1035
Russo EB (2007) History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 4(8):1614–1648
Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M, Bertorelli R, Reggiani A, Piomelli D (2013) Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain 154(3):350–360
Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasson JL, Schmid HH (1995) Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett 375(1–2):117–120
Schmidt ME, Liebowitz MR, Stein MB, Grunfeld J, Van Hove I, Simmons WK, Van Der Ark P, Palmer JA, Saad ZS, Pemberton DJ, Van Nueten L, Drevets WC (2021) The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology 46(5):1004–1010. https://doi.org/10.1038/s41386-020-00888-1. Epub 2020 Oct 18. PMID: 33070154
Shulga YV, Topham MK, Epand RM (2011) Regulation and functions of diacylglycerol kinases. Chem Rev 111(10):6186–6208. Review
Simon GM, Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho- N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem 281(36):26465–26472
Simon GM, Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho- N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283(14):9341–9349
Soliman N, Haroutounian S, Hohmann AG, Krane E, Liao J, Macleod M, Segelcke D, Sena C, Thomas J, Vollert J, Wever K, Alaverdyan H, Barakat A, Barthlow T, Harris Bozer AL, Davidson A, Diaz-delCastillo M, Dolgorukova A, Ferdousi MI, Healy C, Hong S, Hopkins M, James A, Leake HB, Malewicz NM, Mansfield M, Mardon AK, Mattimoe D, McLoone DP, Noes-Holt G, Pogatzki-Zahn EM, Power E, Pradier B, Romanos-Sirakis E, Segelcke A, Vinagre R, Yanes JA, Zhang J, Zhang XY, Finn DP, Rice ASC. (2021, 15 March) A systematic review and meta-analysis of cannabis-based medicines, cannabinoids and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain. https://doi.org/10.1097/j.pain.0000000000002269. Epub ahead of print. PMID: 33729209
Soria G, Mendizábal V, Touriño C, Robledo P, Ledent C, Parmentier M, Maldonado R, Valverde O (2005) Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30:1670–1680
Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B, Di Marzo V (2013) Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS One 8(4):e60040
Steffens M, Feuerstein TJ, van Velthoven V, Schnierle P, Knörle R (2003) Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex. Naunyn Schmiedeberg’s Arch Pharmacol 368(5):432–436
Stella N, Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 425(3):189–196
Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388(6644):773–778
Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215(1):89–97
Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120(8):2953–2966
Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND (2005) Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 164(2):206–213
Thomas EA, Cravatt BF, Danielson PE, Gilula NB, Sutcliffe JG (1997) Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J Neurosci Res 50(6):1047–1052
Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T (1995a) Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 270(40):23823–23827
Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K et al (1995b) Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1254(2):127–134
Ueda N, Tsuboi K, Uyama T (2010) N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res 49(4):299–315. Review
Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J 280(9):1874–1894. Review
van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480(1–3):133–150. Review
Wagenlehner FME, van Till JWO, Houbiers JGA, Martina RV, Cerneus DP, Melis JHJM, Majek A, Vjaters E, Urban M, Ramonas H, Shoskes DA, Nickel JC (2017) Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. Urology 103:191–197. https://doi.org/10.1016/j.urology.2017.02.029. Epub 2017 Feb 27. PMID: 28254462
Wei D, Piomelli D (2015) Cannabinoid-based drugs: potential applications in addiction and other mental disorders. Focus 13(3):307–316. Review
Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, Gall CM, Piomelli D (2015) Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S A 112(45):14084–14089. https://doi.org/10.1073/pnas.1509795112. Epub 2015 Oct 26. PMID: 26504214; PMCID: PMC4653148
Wells DL, Ott CA (2011) The “new” marijuana. Ann Pharmacother 45(3):414–417. Review
Wollner HJ, Matchett JR, Levine J, Loewe S (1942) Isolation of a physiologically active tetrahydrocannabinol from cannabis Sativa resin. J Am Chem Soc 64(1):26–29
Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M, Ye W, Dannals RF, Ravert HT, Nandi A, Rahmim A, Ming JE, Grachev I, Roy C, Cascella N (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage 52(4):1505–1513
Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN, Liang Y, Wang JW (2008) The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 120(1):71–80. Review
Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL (2011) Brain cannabinoid CB2 receptors modulate cocaine’s actions in mice. Nat Neurosci 14(9):1160–1166
Zhu C, Solorzano C, Sahar S, Realini N, Fung E, Sassone-Corsi P, Piomelli D (2011) Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol 79(4):786–792
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this entry
Cite this entry
Jung, KM., Piomelli, D. (2022). Cannabinoids and Endocannabinoids. In: Pfaff, D.W., Volkow, N.D., Rubenstein, J.L. (eds) Neuroscience in the 21st Century. Springer, Cham. https://doi.org/10.1007/978-3-030-88832-9_136
Download citation
DOI: https://doi.org/10.1007/978-3-030-88832-9_136
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-88831-2
Online ISBN: 978-3-030-88832-9
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences